Average Price Target: €0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Medigene in the last 3 months. The average price target is €0.00, with a high forecast of €0.00 and a low forecast of €10,000,000.00. The average price target represents a -100.00% upside from the last price of €4.09.
The current consensus among 0 polled investment analysts is to n/a stock in Medigene. This rating has held steady since October 2020, when it changed from a Hold consensus rating.
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the UniversitÃ© de MontrÃ©al; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.